Affinivax

Affinivax is a clinical-stage biotechnology company specializing in the development of next-generation vaccines and immunotherapies. The company operates in the healthcare and biotechnology market, focusing on infectious and immune-mediated diseases. Affinivax's core technology, the Multiple Antigen Presenting System (MAPS), enables the high-affinity binding of polysaccharides and proteins in a single vaccine. This unique approach induces a broad and protective B and T cell immune response, offering novel preventive and therapeutic solutions. The company's lead vaccine program targets Streptococcus pneumoniae, a significant cause of pneumonia and other serious infections. Affinivax generates revenue through partnerships, grants, and potential future sales of its proprietary vaccines. The company serves healthcare providers, patients, and global health organizations.

Keywords: MAPS technology, vaccines, immunotherapies, Streptococcus pneumoniae, biotechnology, immune response, polysaccharides, proteins, healthcare, clinical-stage.